Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

Maria Ana Ghetie, Erika M. Podar, Amy Ilgen, Brian E. Gordon, Jonathan W. Uhr, Ellen S. Vitetta

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Monoclonal antibodies (mAbs) that exert antitumor activity can do so by virtue of their effector function and/or their ability to signal growth arrest or cell death. In this study, we demonstrate that mAbs which have little or no signaling activity-i.e., anti-CD19, CD20, CD21, CD22 and Her-2- can become potent antitumor agents when they are converted into IgG-IgG homodimers. The homodimers exert antigrowth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and, in the case of the anti-CD19 mAb, did not require an Fc portion. These results offer the possibility that homodimers of other tumor-reactive mAbs which have little antitumor activity as monomers might be potent, anti-tumor agents.

Original languageEnglish (US)
Pages (from-to)7509-7514
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume94
Issue number14
DOIs
StatePublished - Jul 8 1997

Fingerprint

Monoclonal Antibodies
Apoptosis
Growth
Immunoglobulin G
Neoplasms
Antineoplastic Agents
Cell Death

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. / Ghetie, Maria Ana; Podar, Erika M.; Ilgen, Amy; Gordon, Brian E.; Uhr, Jonathan W.; Vitetta, Ellen S.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 94, No. 14, 08.07.1997, p. 7509-7514.

Research output: Contribution to journalArticle

@article{627dde9094ba4c9690832edb509a5ce4,
title = "Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells",
abstract = "Monoclonal antibodies (mAbs) that exert antitumor activity can do so by virtue of their effector function and/or their ability to signal growth arrest or cell death. In this study, we demonstrate that mAbs which have little or no signaling activity-i.e., anti-CD19, CD20, CD21, CD22 and Her-2- can become potent antitumor agents when they are converted into IgG-IgG homodimers. The homodimers exert antigrowth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and, in the case of the anti-CD19 mAb, did not require an Fc portion. These results offer the possibility that homodimers of other tumor-reactive mAbs which have little antitumor activity as monomers might be potent, anti-tumor agents.",
author = "Ghetie, {Maria Ana} and Podar, {Erika M.} and Amy Ilgen and Gordon, {Brian E.} and Uhr, {Jonathan W.} and Vitetta, {Ellen S.}",
year = "1997",
month = "7",
day = "8",
doi = "10.1073/pnas.94.14.7509",
language = "English (US)",
volume = "94",
pages = "7509--7514",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "14",

}

TY - JOUR

T1 - Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

AU - Ghetie, Maria Ana

AU - Podar, Erika M.

AU - Ilgen, Amy

AU - Gordon, Brian E.

AU - Uhr, Jonathan W.

AU - Vitetta, Ellen S.

PY - 1997/7/8

Y1 - 1997/7/8

N2 - Monoclonal antibodies (mAbs) that exert antitumor activity can do so by virtue of their effector function and/or their ability to signal growth arrest or cell death. In this study, we demonstrate that mAbs which have little or no signaling activity-i.e., anti-CD19, CD20, CD21, CD22 and Her-2- can become potent antitumor agents when they are converted into IgG-IgG homodimers. The homodimers exert antigrowth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and, in the case of the anti-CD19 mAb, did not require an Fc portion. These results offer the possibility that homodimers of other tumor-reactive mAbs which have little antitumor activity as monomers might be potent, anti-tumor agents.

AB - Monoclonal antibodies (mAbs) that exert antitumor activity can do so by virtue of their effector function and/or their ability to signal growth arrest or cell death. In this study, we demonstrate that mAbs which have little or no signaling activity-i.e., anti-CD19, CD20, CD21, CD22 and Her-2- can become potent antitumor agents when they are converted into IgG-IgG homodimers. The homodimers exert antigrowth activity by signaling G0/G1 arrest or apoptosis, depending upon which cell surface molecule they bind. This activity is specific and, in the case of the anti-CD19 mAb, did not require an Fc portion. These results offer the possibility that homodimers of other tumor-reactive mAbs which have little antitumor activity as monomers might be potent, anti-tumor agents.

UR - http://www.scopus.com/inward/record.url?scp=0030806221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030806221&partnerID=8YFLogxK

U2 - 10.1073/pnas.94.14.7509

DO - 10.1073/pnas.94.14.7509

M3 - Article

VL - 94

SP - 7509

EP - 7514

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 14

ER -